Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
. As the model develops, you will: enhance and stabilise the presence of osteoclasts in the system and establish reliable osteoblast–osteoclast communication within the chip; design and refine culture
-
You will collaborate with doctoral candidates, postdoctoral researchers, analysts, and clinical researchers conducting patient studies. We encourage active participation in the design and execution
-
priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient engagement, and
-
stress fields); design computational pipelines that integrate image-based anatomy, blood flow physics, and uncertainty quantification; validate the developed methods on retrospective multi-center clinical
-
invasive and non-invasive quantitative brain PET studies; designing model-independent kinetic analysis methods for dynamic PET imaging; developing connectivity analysis techniques for brain LAFOV PET/CT data
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical
-
treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient
-
treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical